Are All Neurodegenerative Diseases Made Equal?

Various neurodegenerative processes result in the development of diseases like Alzheimer’s (AD), Parkinson’s (PD), amyotrophic lateral sclerosis (ALS), and, arguably, multiple sclerosis (MS). Despite years of research, drug discovery initiatives, and promising clinical trials, these diseases remain incurable. But recent studies have suggested common mechanisms underlying these pathologies. Atypical protein assembly resulting in plaque formation is a common pathological finding in both AD and PD, while neuronal death is a primary (ALS) or secondary (MS) hallmark of the disease. For a detailed look at the mechanisms that drive an array of neurodegenerative diseases, The Scientist is bringing together a panel of experts to share their research, discuss current therapeutic approaches, and offer their insights. Come engage with our panel and get the answers you seek.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

The top 5 cybersecurity threats to pharma for 2022

It's no secret that pharma companies are struggling to protect themselves from cyberattacks amid the pandemic. Data breaches are costing the sector around US$5m a year, while one in 10 pharma companies are at risk of a ransomware attack, exacerbated by a perfect storm of shifting to remote working, increased growth, antiquated OT systems and a lack of cybersecurity skills.
Watch Now

2023 Pharma Digital Transformation

Digitalization in the pharmaceutical industry is a pervasive and persistent phenomenon that rapidly changes how patients engage with pharma and purchase drugs. The pandemic has just accelerated the changes which already began before
Watch Now

New drugs for the old enemy

Despite the efforts towards malaria eradication, the latest estimates show that the number of cases is rising and malaria continues to have a devastating impact on the most vulnerable populations.
Watch Now

Advancing Early Cardiovascular Drug Discovery

ICAGEN, INC

Innovation continues to be a primary driver of value in pharmaceutical research. However, simultaneously, research budgets are coming under ever-increasing pressure. As a consequence, pharma is moving toward a so-called open research model, one that dispenses with recurrent fixed costs in favor of a more flexible and dynamic external “spend.” By adopting this model, pharma could tap into innovation outside their walls. In this webinar, case studies will be presented highlighting the value of such collaborations, while focusing on discovery campaigns that employ highly relevant functional assays.
Watch Now